Literature DB >> 8926632

Localization and synthesis of acetylcholine in human leukemic T cell lines.

T Fujii1, T Tsuchiya, S Yamada, K Fujimoto, T Suzuki, T Kasahara, K Kawashima.   

Abstract

In order to clarify the origin of acetylcholine (ACh) in human blood, we measured the content and synthesis activity of ACh in several human leukemic cell lines. The intracellular ACh content determined by a specific and sensitive radioimmunoassay in the human leukemic T cell lines, HSB-2, MOLT-3, and CEM, was 79.6, 36.2, and 9.5 pmol/10(6) cells, respectively. These values were 9-70-fold higher than those of other cell lines, including a helper T cell line, Jurkat. Stimulation of HSB-2 and MOLT-3 by phytohemagglutinin (PHA) increased both the intracellular content and release of ACh into the culture medium, but did not influence the intracellular content and release of ACh in CEM. ACh synthesis activity was found in all the T cell lines tested. Bromoacetylcholine (100 microM), a choline acetyltransferase (ChAT) inhibitor, and bromoacetyl-L-carnitine (100 microM), a carnitine acetyltransferase (CarAT) inhibitor, decreased ACh-synthesizing activity in MOLT-3, and HSB-2 and CEM, by about 50% and 30%, respectively, indicating that both ChAT, and to a lesser extent CarAt, are involved in ACh synthesis in T cells. These results suggest that T lymphocytes have the potential to synthesize and release ACh, which may play a role in regulating T cell-dependent immune responses.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8926632     DOI: 10.1002/(SICI)1097-4547(19960401)44:1<66::AID-JNR9>3.0.CO;2-G

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  18 in total

1.  Upregulation of mRNA encoding the M5 muscarinic acetylcholine receptor in human T- and B-lymphocytes during immunological responses.

Authors:  Takeshi Fujii; Yoshihiro Watanabe; Tomoyuki Inoue; Koichiro Kawashima
Journal:  Neurochem Res       Date:  2003-04       Impact factor: 3.996

Review 2.  Overview of therapeutic applications of non-invasive vagus nerve stimulation: a motivation for novel treatments for systemic lupus erythematosus.

Authors:  Charrise M Ramkissoon; Amparo Güemes; Josep Vehi
Journal:  Bioelectron Med       Date:  2021-05-25

3.  Analysis of CD8+ T cell-mediated anti-viral responses in mice with targeted deletions of the M1 or M5 muscarinic cholinergic receptors.

Authors:  Vaiva Vezys; David Masopust; Maxime Desmarets; Jürgen Wess; James C Zimring
Journal:  Life Sci       Date:  2007-01-13       Impact factor: 5.037

Review 4.  Muscarinic receptors and ligands in cancer.

Authors:  Nirish Shah; Sandeep Khurana; Kunrong Cheng; Jean-Pierre Raufman
Journal:  Am J Physiol Cell Physiol       Date:  2008-11-26       Impact factor: 4.249

Review 5.  Autonomic regulation of T-lymphocytes: Implications in cardiovascular disease.

Authors:  Safwan K Elkhatib; Adam J Case
Journal:  Pharmacol Res       Date:  2019-06-06       Impact factor: 7.658

6.  Cardiac acetylcholine inhibits ventricular remodeling and dysfunction under pathologic conditions.

Authors:  Ashbeel Roy; Mouhamed Dakroub; Geisa C S V Tezini; Yin Liu; Silvia Guatimosim; Qingping Feng; Helio C Salgado; Vania F Prado; Marco A M Prado; Robert Gros
Journal:  FASEB J       Date:  2015-10-19       Impact factor: 5.191

7.  Neural control of the immune system.

Authors:  Eva Sundman; Peder S Olofsson
Journal:  Adv Physiol Educ       Date:  2014-06       Impact factor: 2.288

Review 8.  Cholinergic System and Its Therapeutic Importance in Inflammation and Autoimmunity.

Authors:  Namrita Halder; Girdhari Lal
Journal:  Front Immunol       Date:  2021-04-15       Impact factor: 7.561

9.  Hemicholinium-3 sensitive choline transport in human T lymphocytes: Evidence for use as a proxy for brain choline transporter (CHT) capacity.

Authors:  Ajeesh Koshy Cherian; Vinay Parikh; Qi Wu; Yang Mao-Draayer; Qin Wang; Randy D Blakely; Martin Sarter
Journal:  Neurochem Int       Date:  2017-05-31       Impact factor: 3.921

Review 10.  Cholinergic activity as a new target in diseases of the heart.

Authors:  Ashbeel Roy; Silvia Guatimosim; Vania F Prado; Robert Gros; Marco A M Prado
Journal:  Mol Med       Date:  2015-01-26       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.